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Abstract 
Background: The Democratic Republic of Congo (DRC) is one of the two most leading contributors to the global 
burden of disease due to malaria. This paper describes the malaria testing and treatment market in the nation’s capital 
province of Kinshasa, including availability of malaria testing and treatment and relative anti-malarial market share for 
the public and private sector.
Methods: A malaria medicine outlet survey was conducted in Kinshasa province in 2013. Stratified multi-staged sampling 
was used to select areas for the survey. Within sampled areas, all outlets with the potential to sell or distribute anti-malarials 
in the public and private sector were screened for eligibility. Among outlets with anti-malarials or malaria rapid diagnostic 
tests (RDT) in stock, a full audit of all available products was conducted. Information collected included product information 
(e.g. active ingredients, brand name), amount reportedly distributed to patients in the past week, and retail price.
Results: In total, 3364 outlets were screened for inclusion across Kinshasa and 1118 outlets were eligible for the 
study. Among all screened outlets in the private sector only about one in ten (12.1%) were stocking quality-assured 
Artemisinin-based Combination Therapy (ACT) medicines. Among all screened public sector facilities, 24.5% had both 
confirmatory testing and quality-assured ACT available, and 20.2% had sulfadoxine-pyrimethamine (SP) available for 
intermittent preventive therapy during pregnancy (IPTp). The private sector distributed the majority of anti-malarials 
in Kinshasa (96.7%), typically through drug stores (89.1% of the total anti-malarial market). Non-artemisinin therapies 
were the most commonly distributed anti-malarial (50.1% of the total market), followed by non quality-assured ACT 
medicines (38.5%). The median price of an adult quality-assured ACT was $6.59, and more expensive than non quality-
assured ACT ($3.71) and SP ($0.44). Confirmatory testing was largely not available in the private sector (1.1%).
Conclusions: While the vast majority of anti-malarial medicines distributed to patients in Kinshasa province are sold 
within the private sector, availability of malaria testing and appropriate treatment for malaria is alarmingly low. There 
is a critical need to improve access to confirmatory testing and quality-assured ACT in the private sector. Widespread 
availability and distribution of non quality-assured ACT and non-artemisinin therapies must be addressed to ensure 
effective malaria case management.
Keywords: Democratic Republic of the Congo, Artemisinin-based combination therapy, ACT, Rapid diagnostic test, 
Market share, Availability antimalarial
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Background
The Democratic Republic of Congo (DRC) is the sec-
ond largest contributor to the global burden of disease 
due to malaria [1]. Malaria accounts for more than 40% 
of all outpatient visits and is the main cause of morbidity 
and mortality [1]. Of notable public health concern is the 
capital city of Kinshasa, which hosts up 15% of the DRC’s 
79 million people [2]. Malaria prevalence is diverse given 
the geographical make-up of the city, with densely popu-
lated areas separated by large semi-rural areas, and with 
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some of the areas completely rural in nature [3]. Recent 
evidence suggests malaria prevalence is around 11.9% in 
children 6–59 months, and as high as 31.7% in semi-rural 
areas of the city [3], illustrating not only the diversity of 
malaria prevalence and risk in Kinshasa, but that malaria 
is of grave public health concern in this populous area, a 
finding supported by earlier research [4, 5].
Ensuring that febrile patients in Kinshasa have access 
to confirmatory malaria testing and affordable arte-
misinin-based combination therapy (ACT)—the first-line 
treatment for uncomplicated malaria—will be central to 
ensuring patients are managed correctly in accordance 
with the national malaria control guidelines. The DRC 
malaria treatment guidelines state that all suspected 
cases should be confirmed by diagnostic testing prior 
to treatment. Positive cases of simple malaria should 
be treated with artesunate  +  amodiaquine (ASAQ) or 
artemether  +  lumefantrine (AL), ideally with a World 
Health Organization (WHO) pre-qualified product, 
referred to as a quality-assured ACT.
A 2009 survey conducted by the ACTwatch project [6] 
revealed that there are several barriers to appropriate 
treatment in the DRC—namely that availability of qual-
ity-assured ACT medicines in the private sector, where 
most people seek treatment, is low (Table 1) [7]. In 2009, 
only 14% of the anti-malarial stocking private sector had 
quality-assured ACT available. Furthermore, ACT medi-
cines that were available in the private sector were namely 
non quality-assured. Oral artemisinin monotherapy was 
sold and distributed in the private sector, and contrib-
uted up to 10% of the total market share of all anti-malar-
ials. Due to the threat that oral artemisinin monotherapy 
poses for the development of artemisinin resistance, this 
class of anti-malarial medicine was banned in the DRC in 
2009 [1]. Finally, availability of malaria diagnosis was low 
in the private sector and restricted to private for-profit 
health facilities (21%). Availability was higher in the pub-
lic sector, with around 80% of this sector stocking a diag-
nostic test.
In 2013, a follow-up outlet survey was conducted in 
Kinshasa to understand the extent to which the anti-
malarial landscape has changed over time. The paper pro-
vides a descriptive illustration of Kinshasa’s anti-malarial 
market as a means to understand current barriers regard-
ing access to appropriate malaria case management 
and to guide future malaria interventions designed to 
improve access to affordable quality-assured ACT and 
confirmatory testing.
Methods
The ACTwatch project is a multi-country research pro-
ject implemented by Population Services International 
(PSI) and was launched in 2008 [6]. The ACTwatch pro-
ject provides information on anti-malarial market evi-
dence to inform case management strategies, and to 
monitor national and global policy and funding decisions 
[8, 9]. Outlet survey data are collected to understand the 
supply side of malaria medicine and diagnostic markets 
[10].
Design and sample
A sub-national representative cross-sectional malaria 
medicine outlet survey was conducted in Kinshasa 
(11th September—11th October 2013). Methods for 
the surveys have been described in detail previously [6, 
9]. Briefly, clusters with a population size of approxi-
mately 10,000 to 15,000 inhabitants, (“aires de santé”) 
were selected with probability proportional to size from 
a list of all clusters in Kinshasa province. Explicit strati-
fication was used to sample from urban and rural areas 
of the province. All outlets with the potential to provide 
malaria medicine or testing were screened within each 
cluster to determine availability of malaria diagnostics 
and medicines. In the public sector, this included pub-
lic health facilities and not-for-profit health facilities. In 
the private sector, this included private for-profit health 
facilities, pharmacies, drug stores, general retailers and 
itinerant drug vendors. Outlets were included in the sur-
vey if they had an anti-malarial in stock, or anti-malarials 
in stock in the past three months preceding the survey, or 
had malaria testing available.
The study was powered to detect a minimum of a 
20% point change in availability of quality-assured ACT 
among anti-malarial stocking outlets with 80% power 
and 95% significance.
Table 1 Key results from  2009 ACTwatch survey in  Kin-
shasa
Dates of data collection August–September 
2009
Sample N
Outlets screened 2368
Outlets interviewed 778
Among all screened outlets, percentage that 
had
% (95% CI)
Public sector availability of quality-assured ACT 48.5 (32.8, 64.6)
Private sector availability of quality-assured ACT 14.1 (10.6, 18.6)
Public sector availability of non quality-assured ACT 20.0 (11.4, 32.8)
Private sector availability of non quality-assured 
ACT
60.7 (55.2, 66.0)
Public sector availability of oral artemisinin mono-
therapy
26.0 (15.4, 40.3)
Private sector availability of oral artemisinin mono-
therapy
70.4 (65.4, 75.0)
Anti-malarial market share %
Market share of oral artemisinin monotherapy 10.8
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Procedures
Outlets were identified using a census procedure within 
each of the selected clusters. All outlets were approached 
and administered a set of screening questions to deter-
mine eligibility. Outlets were eligible if they had an anti-
malarial in stock on the day or survey or in the past three 
months. An interview with the staff member who was 
most likely to sell or prescribe medications was con-
ducted. The interview was carried out in French or in 
local language (Lingala).
Measures
A structured questionnaire included an audit of all avail-
able anti-malarials and malaria rapid diagnostic tests 
(RDTs). The audit captured product information includ-
ing formulation, strength, brand name, active ingredients, 
manufacturer, and country of manufacture. Information 
was also collected on the retail price and the amount of 
the medicine sold in the last week, or number of RDTs 
performed in the past week. Availability, price and num-
ber of tests performed by microscopy was also collected.
Data analysis
Double data entry was conducted using Microsoft Access 
(Microsoft Corporation, Redmond, Washington, USA) 
with built-in range and consistency checks. Data were 
analyzed across survey rounds using Stata (StataCorp 
College Station, TX). Stata survey settings were used to 
account for the stratified and clustered sampling strat-
egy and to apply sampling weights. Sampling weights 
were calculated as the inverse of the probability of cluster 
selection.
Standard indicators were constructed according to 
definitions applied across the ACTwatch project and 
have been described elsewhere [20, 21]. For all key 
indicators, anti-malarials were categorized as ACT, 
non-artemisinin therapy or artemisinin monotherapy 
according to active ingredients. Artemisinin mono-
therapies were further classified as oral or non-oral to 
distinguish between the banned oral artemisinin mono-
therapies, and the non-oral artemisinin monotherapies, 
which may be used for treatment of severe malaria. ACT 
medicines were further classified as quality-assured or 
non quality-assured according to product information 
including active ingredients, strengths, manufacturer 
and country of manufacture. This product information 
was matched to lists of pre-qualified ACT medicines 
from the WHO and the Global Fund to identify quality-
assured ACT that are manufactured according to global 
quality standards. Non quality-assured ACT medicines 
are defined as ACT medicines that do not have WHO 
pre-qualification or approval for procurement by the 
Global Fund.
Availability was determined according to the physical 
presence of anti-malarial medicines during the prod-
uct audit. Anti-malarial availability was measured as the 
percent of outlets with each type of anti-malarial noted 
above in stock on the day of the survey. The volumes of 
the anti-malarials distributed were standardized using 
the adult equivalent treatment dose (AETD) to allow cal-
culation of relative market share for types of anti-malar-
ials, including tablet and all non-tablet dosage forms. 
The AETD is defined as the amount of active ingredient 
required to treat an adult weighing 60  kg according to 
WHO treatment guidelines [22]. Provider reports on the 
amount of the drug sold or distributed during the week 
preceding the survey were used to calculate volumes 
distributed. Relative market share was calculated as the 
amount of anti-malarial medicine distributed in the past 
week within each anti-malarial drug category (quality-
assured and non quality-assured ACT, non-artemisinin 
therapy, oral artemisinin monotherapy, and non-oral 
artemisinin monotherapy), divided by the total anti-
malarial distribution.
The AETD was also used for comparing the median 
private sector price for different anti-malarial medicines. 
Price was calculated for tablet formulation only given 
the difference in price across drug formulation. Provider 
reports for retail prices were converted to US dollars 
using official exchange rates. Median price and the inter-
quartile range were calculated.
Results
In total, 3364 outlets were screened for inclusion across 
Kinshasa and 1118 eligible outlets were interviewed and 
included in the analysis. Outlets stocking anti-malarials 
included public and private not-for-profit and for-profit 
health facilities, pharmacies, and drug stores. More than 
2100 general retail outlets were screened, however anti-
malarial medicines were not found in the general retail 
sector (Table  2). Of the outlets screened, 141 facili-
ties had only diagnostic testing available and were not 
included in the analysis. Among outlets with anti-malar-
ials in stock on the day of interview, 12,291 anti-malarial 
products were audited. In total, 278 RDT products were 
audited.
All public and private health facilities and pharmacies 
and 98.6% of drug stores stocking anti-malarial medi-
cines reportedly employed a provider who completed 
secondary school. In addition, all public health facilities 
and pharmacies, nearly all private not-for-profit (99.5%) 
and for-profit health facilities (99.7%), and 82.2% of drug 
stores reportedly employed a provider with a formal 
health qualification in medicine, pharmacy, nursing, mid-
wifery or community health work (see Additional file 1: 
Table S1).
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Anti‑malarial market composition
Figure 1 shows the relative distribution of all outlets that 
had at least one anti-malarial in stock (n = 917). The anti-
malarial market in Kinshasa was dominated by the pri-
vate sector, and in particular by drug stores. Drug stores 
accounted for 80% of anti-malarial-stocking outlets in 
2013, while private for-profit health facilities comprised 
15% of the market. The public sector (public health facili-
ties and private not-for profit facilities), accounted for 
less than 5% of the market composition.
Availability of anti‑malarials
Figure 2 shows availability of different classes of anti-
malarials as the proportion of anti-malarial stocking 
outlets. Among the anti-malarial stocking public sec-
tor, 49.7% had quality-assured ACT in stock compared 
to 12.1% in the private sector. Within the anti-malarial 
stocking private sector, less than 10% of drug stores 
and only one in five private for-profit health facili-
ties (24.7%) were found to stock quality-assured ACT. 
Availability of non quality-assured ACT medicines was 
much higher in the private sector. Over 80% of pri-
vate sector outlets stocked non quality-assured ACT 
compared to 23.2% among public sector outlets. Non 
quality-assured ACT was commonly available in anti-
malarial-stocking drug stores (90.5%), and private-for 
profit health facilities showed moderate availability 
Table 2 Results of the outlet census
a No anti-malarials in stock on the day of the survey
N Public sector Private sector
Public 
facility
Private not‑for‑
profit facility
Private for‑
profit facility
Pharmacy Drug 
store
General 
retailer
Itinerant 
drug vendor
Outlets screened 3364 26 66 367 3 741 2149 12
Eligible outlets
 Anti-malarial in stock 962 21 41 174 3 722 1 0
 Anti-malarial in stock in the past 
3 monthsa
45 4 6 28 0 10 0 0
 Malaria testing availablea 142 4 16 122 0 0 0 0
Outlets interviewed
 Anti-malarial in stock in the past 
3 monthsa
932 21 41 173 3 693 1 0
 Malaria testing availablea 45 1 6 28 0 10 0 0
 Malaria testing available 141 4 16 121 0 0 0 0
Products audited
 Anti-malarials 12,291 109 169 815 85 11,111 2 0
 Malaria RDTs 278 8 13 54 1 3 0 0
N=962
Public health facility
Private not-for-profit health
facility
Private for-profit health
Facility
Pharmacy
Drug shop
General retailer
Fig. 1 Anti-malarial market composition
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Fig. 2 Anti-malarial availability among anti-malarial stocking outlets
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(44.0%). Non-artemisinin therapies were more com-
monly available in the private sector (typically sul-
fadoxine-pyrimethamine [SP] 65.4%; oral quinine 
84.6%) as compared with the public sector (SP, 34.9%; 
oral quinine 52.6%). Availability of oral artemisinin 
monotherapy was <1% in the private sector and 0% in 
the public sector.
Anti‑malarial market share
Figure  3 shows the relative anti-malarial market share 
for public and private sector and by type of anti-malar-
ial medicine. Ninety-seven percent of all anti-malarials 
distributed to consumers in the week preceding the sur-
vey were distributed through the private sector. Most of 
the anti-malarials were distributed through drug stores 
(89.1% of the total anti-malarial market share).
Non-artemisinin therapies were the most commonly 
distributed anti-malarial (50.1% of the total market 
share). These included SP (31.1%) and quinine (19.0%). 
Non quality-assured ACT medicines accounted for 38.5% 
of all anti-malarials distributed. Quality-assured ACT 
medicines accounted for less than 5% of the total mar-
ket share. Oral artemisinin monotherapy market share 
was <0.1%.
Non quality‑assured ACT in the private for‑profit sector
Figure 4 presents the frequency distribution by generic 
type and formulation of the 5982 non quality-assured 
ACT medicines audited in the private sector. Most 
non quality-assured ACT medicines available were 
artemether-lumefantrine (AL) suspensions (38%, 18 
unique brands), AL tablets (31%, 15 unique brands) 
or suspensions (11%, 7 unique brands). Other types 
of non quality-assured ACT medicines included 
dihydroartemisinin-piperaquine tablets (5%, 5 unique 
brands) and suspensions (9%, 6 unique brands); as well 
as dihydroartemisinin-SP tablets (3%, 1 brand) and 
artesunate-amodiaquine tablets (3%, 5 unique brands).
Price of anti‑malarials
The median [inter-quartile range] price in drug shops 
for one adult equivalent treatment dose of quality-
assured ACT was $6.59 [$2.75–$9.89], compared to $3.85 
[$3.30–$4.94] for non quality-assured ACT. The median 
quality-assured ACT price in private for-profit facilities 
was $0.00, while non quality-assured ACT was on aver-
age sold at $3.71 [$2.75–$4.94]. SP was the cheapest tablet 
anti-malarial in the private for-profit sector ($0.44 [$0.33–
$0.55] for one AETD).
Readiness for malaria case management: availability 
of quality‑assured ACT and malaria diagnosis, 
and availability of intermittent preventive therapy 
during pregnancy (IPTp)
Table  3 summarizes availability of key commodities for 
appropriate malaria case management and for provision 
of IPTp among all screened outlets (including outlets 
with and without anti-malarials on the day of the survey), 
0
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Fig. 3 Anti-malarial market share
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as a means to show the extent to which different outlet 
types are able to provide nationally recommended case 
management commodities.
Public sector readiness for malaria case manage-
ment was overall low with only one in four public 
sector outlets stocking both malaria testing and qual-
ity-assured ACT (24.5%). While availability of con-
firmatory testing was high (86.8%), availability of 
quality-assured ACT was much lower (28.7%). Avail-
ability of SP for ITPp was also low; only one in five 
Fig. 4 Distribution of non quality-assured ACT available in the private sector, 2013.
Notes Types of non quality-assured ACT audited in private sector outlets by generic type and dosage form, Kinshasa 2013 (n = 5,982, unweighted). 
Other generic tablets audited but comprising <1% total share were artesunate-mefloquine, dihydroartemisininpiperaquine-trimethoprim and 
artemisinin-piperaquine. AL artemether-lumefantrine; AS-SP artesunate-SP; DHA-PPQ dihydroartemisinin-piperaquine; ASAQ artesunate-amodi-
aquine. asterisk The unique brand counts does not differentiate tablet strengths or age/weight bands for the same branded product (e.g. Brand X of 
AL 20mg/120mg and Brand X of AL 40mg/240mg are counted as one unique brand, brand X).
Table 3 Readiness for malaria case management in the public and private sector, among all screened outlets
Percent (95% confidence interval [CI])
Total Public Sector Private for‑profit 
health facility
Drug store Total Private Sector
N = 92 N = 367 N = 741 N = 3272
Any malaria blood testing 86.8 (75.9, 93.2) 75.5 (64.9, 83.7) 0.3 (0.1, 1.5) 7.3 (6.1, 8.7)
Malaria microscopy 82.9 (72.0, 90.2) 72.9 (62.8, 81.1) 0.0 7.0 (5.8, 8.3)
RDT 21.8 (12.3, 35.8) 14.0 (10.3, 18.7) 0.3 (0.1, 1.4) 1.4 (1.0, 2.0)
Quality-assured ACT 28.7 (17.5, 43.2) 12.5 (8.2, 18.5) 8.6 (5.5 13.2) 3.3 (2.5, 4.4)
Readiness for malaria case management: 
Malaria testing and quality-assured ACT available
24.5 (15.0, 39.6) 10.7 (7.2, 15.6) 0.3 (0.1, 1.5) 1.1 (0.7, 1.7)
Readiness for IPTp: 
SP available
20.2 (11.7, 32.5) 12.0 (8.1, 17.5) N/a N/a
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public facilities had SP available on the day of the sur-
vey (20.2%).
In the private sector, only 1.1% of outlets had both 
confirmatory testing and quality-assured ACT available. 
Readiness was higher among private for-profit facilities 
(10.7%) as compared with drug stores (0.3%).
Discussion
Data from a 2013 representative medicine outlet survey 
in Kinshasa confirm the importance of the private sector 
as a source of anti-malarial treatment, particularly drug 
stores. Results suggest urgent need to address malaria 
case management in the private sector, remove non qual-
ity-assured ACT medicines and inefective nonartemisin-
intherapies from the market, and address gaps in public 
sector readiness for appropriate case management.
Urgent need to address malaria case management in the 
private sector
The distribution of anti-malarials in Kinshasa in 2013 was 
heavily dominated by the private sector, particularly drug 
stores which comprised almost 90% of the anti-malarial 
service delivery points. Drug stores in Kinshasa are not 
registered or regulated by a government authority, and 
are not authorized to test for malaria using RDTs. How-
ever, the vast majority of people receiving anti-malarial 
treatment in Kinshasa are receiving medicines from these 
unregistered and unregulated points of care where con-
firmatory testing is not permitted and quality-assured 
ACT treatment and malaria diagnostic testing is gener-
ally not available. With the vast majority of the antimalar-
ial distribution moving through drug stores, these outlets 
most commonly stock and distribute non quality-assured 
ACT medicines and non-artemisinin therapies.
The finding that most of the anti-malarial medicine 
market share is comprised of drug stores in Kinshasa may 
provide an opportunity to increase access to affordable, 
quality-assured ACT medicines, as evidenced in other 
countries where these facilities are a common source 
of treatment [11–13]. The affordable medicines facility, 
malaria (AMFm), a large scale pilot to increase access to 
subsidized quality-assured ACT, demonstrated signifi-
cant improvements in availability, affordability and rela-
tive market share for these medicines among the private 
sector and in drug stores in particular [14]. Since the 
AMFm pilot, follow-up ACTwatch surveys have shown 
a sustained improvement in the availability of quality-
assured ACT medicines among drug stores in these 
countries [11–13]. The success of the private sector co-
payment mechanism in these countries suggests that a 
similar strategy could be effective in improving the avail-
ability, affordability and market share for quality-assured 
ACT in Kinshasa.
Several countries have implemented successful inter-
ventions aimed at specifically strengthening drug stores 
for malaria case management. In Nigeria, Tanzania 
and Uganda, registration or accreditation programmes 
have been implemented in recent years to ensure that 
drug store providers are trained to assess and treat sus-
pected malaria. For example, since 2006 the Tanzanian 
government has been in the process of accrediting drug 
dispensing outlets (ADDOs) to sell a limited range of 
prescriptions only medicines, including quality-assured 
ACT, after participation in a 35-day training programme. 
More recently, pilot initiatives have introduced RDTs into 
ADDOs with relative success, demonstrating patient will-
ingness to pay for an RDT and an increased likelihood to 
purchase an ACT medicine [15]. Other research shows 
similar findings from a pilot test in Uganda where RDTs 
were introduced among drug stores that were licensed 
by the Ugandan Ministry of Health. The study concluded 
that by offering provider training and access to subsidized 
RDTs, it was possible to increase malaria testing rates sig-
nificantly within communities [16]. These programmes 
demonstrate the feasibility of providing confirmatory 
testing and quality-assured ACT at these common points 
of care for suspected malaria, which is a common source 
of treatment in Kinshasa—as evidenced by other stud-
ies [17]. Approaches to engaging drug stores in Kinshasa 
with accreditation or other registration, training and 
supervision programmes could be promising for increas-
ing coverage of confirmatory testing prior to treatment 
and improving access to quality-assured ACT.
Widespread availability and distribution of inappropriate 
anti‑malarial medicines
In 2009, the vast majority of anti-malarial-stocking out-
lets in Kinshasa were stocking oral artemisinin mono-
therapy. By 2013, oral AMT had disappeared from the 
market, demonstrating the success of the drug ban which 
had been implemented in 2009 [18].
Despite this achievement, multiple threats to effective 
malaria case management persist in the anti-malarial 
market in 2013. First is the widespread availability of non 
quality-assured ACT medicines. These are combination 
therapies that are not manufactured according to global 
standards set by the World Health Organization [19] and 
include up to 57 different brands with a spectrum of dif-
ferent formulations and active ingredients, though most 
commonly were either AL suspensions or tablets. While 
it was beyond the scope of this study to test the drug 
quality and efficacy of these products, the availability of 
multiple generics, formulations and brands which do not 
conform to global quality standards is of concern given 
the threats to effective parasite clearance and potential to 
contribute to artemisinin resistance.
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The availability and distribution of non quality-assured 
ACT medicines is a growing problem documented in 
other countries by the ACTwatch project, including 
Kenya and Nigeria [20, 21]. However, levels of availability 
and distribution are much higher in Kinshasa and this is 
of particular concern given the significant malaria burden 
in the DRC. Non quality-assured products are commonly 
manufactured in the DRC and such locally-manufactured 
ACT medicines may also be prone to a number of risk 
factors for sub-standard quality, such as poor drug regu-
lation and technical capacity in their development [22]. 
Given their lack of quality-assured status, these medi-
cines have not been subjected to international good 
manufacturing practices and may have contents or dis-
solution times that are outside the acceptable limits due 
to poor quality control [23]. Other research that tested 
ACT formulations for their drug quality has shown that 
quality-assured ACT medicines have 0.1 times the odds 
of being poor quality compared with non quality-assured 
ACT (0.5% of quality-assured ACT tested were of poor 
quality compared to 5.4% of those non quality-assured 
ACT). Additional analysis revealed that products with 
quality-assured status remained significantly associated 
with anti-malarial medicine being of acceptable quality 
[24]. The results indicate that important improvements 
in quality can be achieved by ensuring that only prod-
ucts meeting WHO prequalification are registered and 
allowed on the market. The replacement of non quality-
assured ACT with quality-assured ACT from the Kin-
shasa market will be important to ensure febrile children 
and adults have access to effective, first-line treatment.
The 2013 outlet survey also documented ongoing high 
levels of availability and distribution of non-artemisinin 
therapies, which are no longer recommended for uncom-
plicated malaria case management in the DRC. Non-arte-
misinin therapies accounted for half of all anti-malarials 
distributed in Kinshasa. These include oral quinine and 
SP. Although SP may be used for IPTp, availability and 
distribution through drug stores as opposed to health 
facilities, as well as product packaging and patient 
instructions on SP products promoting use for malaria 
case management for people of all ages, suggests that 
SP is being used as an inexpensive treatment for malaria 
[25]. The results also demonstrate that SP is far less 
expensive than quality-assured ACT in the private sec-
tor. These results point to the need to replace ineffective 
and non-recommended non-artemisinin therapies with 
quality-assured ACT medicines. The aforementioned 
AMFm pilot is one strategy which has shown promise in 
reducing stockage and distribution of non-artemisinin 
therapies, however challenges with availability and dis-
tribution of these products persist in the former AMFm 
countries given the relatively low cost of non-artemisinin 
monotherapies [26].
Gaps in public and private sector readiness to manage 
malaria
The DRC was one of the first countries to adopt the sec-
ond edition of the World Health Organization’s malaria 
treatment guidelines [27], for which a cornerstone of 
these guidelines was the recommendation to provide 
confirmatory diagnostic testing for all febrile patients, 
even in children under the age of five. Results from the 
2013 outlet survey in Kinshasa demonstrate that nearly 
90% of public facilities in Kinshasa have confirmatory 
testing available, primarily through malaria microscopy 
as opposed to RDTs. However, significant gaps persist in 
availability of quality-assured ACT, with fewer than one-
third of public sector outlets stocking quality-assured 
ACT. Overall, only one in four public sector outlets have 
both confirmatory testing and quality-assured ACT avail-
able. Only one in five public outlets had SP available for 
IPTp during antenatal care visits.
Kinshasa’s readiness for appropriate malaria case man-
agement was extremely low in the private sector, and 
in particular among drug stores where most patients 
receive anti-malarial treatment. In drug stores, there 
was negligible availability of diagnostic tests and qual-
ity-assured ACT, pointing to the need to reinforce and 
promote the necessity of diagnostic testing among both 
providers and patients, while ensuring commodities 
are available and affordable within this sector as well as 
the public sector. Low availability of confirmatory test-
ing in particular threatens appropriate management of 
suspected cases, spurring the potential for presumptive 
anti-malarial treatment. The low availability of confirma-
tory testing also merits a revisit of national policy to 
permit testing within these outlet types and provision of 
quality-assured treatment. As discussed previously, sev-
eral initiatives in other countries have introduced RDTs 
into drug stores with relative success [15, 16], demon-
strating the feasibility of providing confirmatory testing 
in the private sector.
Implications
Given significant gaps in readiness for malaria case 
management documented in 2013, several measures 
were taken by the National Malaria Control Programme 
(PNLP), and with support from the Department For 
International Development (DFID), GFTAM, Associa-
tion de Santé Familiale (ASF) and Population Services 
International (PSI), to transform the private sector anti-
malarial market to improve quality malaria case man-
agement in Kinshasa [28]. This has included improving 
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coordination between authorities and strengthening of 
the regulatory environment, establishing price reductions 
and increasing consumer demand for quality-assured 
ACT and fostering private sector case management. 
Over three and a half million quality-assured, subsidized 
ACT courses have been delivered over the course of the 
project and a further 1.7 million RDT. It is expected that 
future ACTwatch surveys will be able to document these 
achievements.
Limitations
The data presented in this paper are representative for 
Kinshasa province only. Given the importance of the 
DRC with respect to global malaria burden, a key limi-
tation is the lack of information on malaria markets in 
other areas of the DRC. Other limitations to the ACT-
watch survey methodology have been described else-
where in detail [10].
Conclusions
While incredible progress has been made in recent 
years in improving access to malaria testing and qual-
ity-assured first-line treatment in many countries in 
sub-Saharan Africa [1], progress in the DRC has largely 
been absent. Given the significant burden of malaria in 
this country, there is urgent need to address gaps in both 
the public and private sector. Evidence from this study 
suggests that working with the private sector to remove 
non quality-assured ACT medicines and ineffective non-
artemisinin therapies and to increase the availability and 
quality-assured ACT and confirmatory testing will be 
necessary to ultimately improve malaria case manage-
ment in Kinshasa.
Abbreviations
AETD: adult equivalent treatment dose; ACT: artemisinin-based combination 
therapy; AL: artemether-lumefantrine; ASF: Association de Santé Familiale; 
DFID: Department For International Development; DRC: Democratic Republic 
of Congo; IPTp: intermittent preventivetherapy during pregnancy; PSI: Popula-
tion Services International; RDT: rapid diagnostic test.
Authors’ contributions
The manuscript was written by members of the ACTwatch Group: Kathryn A. 
O’Connell and Megan A. Littrell. Data cleaning and analysis was completed by 
members of the ACTwatch Group: Julie Archer, ML, Kevin Duff and Stephen 
Poyer. GM, AT and JLL contributed to data interpretation and manuscript 
drafts. All authors read and approved the final manuscript.
Author details
1 Population Services International, 1120 19th St NW Suite 600, Washington, 
DC 20036, USA. 2 Association de Santé Familial, 4630 Avenue de la Science, 
Immeuble USTC, Bloc C, Gombe, Kinshasa, Democratic Republic of Congo. 
Additional file
Additional file 1: Table S1. Provide demographics.
3 Ecole de Santé Public de Kinshasa, Kinshasa, Democratic Republic of Congo. 
4 National Malaria Control Programme, Kinshasa, Congo. 
Acknowledgements
We would like to thank Jamie Ciesla and Willy Onema of the Association de 
Santé Familiale; and support from the National Malaria Control Programme. 
The authors are grateful to the field teams from the Ecole de Santé Public 
de Kinshasa who undertook the survey and to the study participants for 
their time and participation. This study received financial support from the 
United Kingdom Department For International Development and the Bill and 
Melinda Gates Foundation. 
ACTwatch Group (2008-2017): Angela Alum; Andrew Andrada; Julie 
Archer; Erick Auko; Dr. Katie Bates; Dr. Paul Bouanchaud; Meghan Bruce; 
Angela Camilleri; Emily Carter; Dr. Steven Chapman; Nikki Charman; Dr. 
Desmond Chavasse; Kevin Duff; Keith Esch; Anna Fulton; Illah Evance; Anna 
Fulton; Hellen Gataaka; Tarryn Haslam; Emily Harris; Catharine A. Hurley; Beth 
Kangwana; Esther Kabui; Gloria Kigo; Aliza Lailari; Dr. Megan Littrell (Principal 
Investigator, 2014-2017); Erik Munroe Julius Ngigi; Dr. Kathryn A. O’Connell 
(Principal Investigator, 2008-2012); Ricki Orford; Carolyne Ochieng; Linda Ong-
wenyi; Stephen Poyer; Dr. Justin Rahariniaina; Lanto Razafindralambo; Christina 
Riley; Dr. John Rodgers; Tanya Shewchuk; Julianna Smith; Tsione Solomon; 
Raymond Sudoi; Martine Esther Tassiba; Katherine Thanel; Dr. Andria Rusk; 
Julianna Smith; Rachel Thompson; Mitsuru Toda; Marie-Alix Valensi; Dr. Vamsi 
Vasireddy (Principal Investigator, 2013); Cynthia Whitman.
Competing interests
The authors declare that they have no competing interests.
Availability of data and material
ACTwatch data is made publically available to any interested party. To request 
a dataset please contact the project Principal Investigator to receive to 
complete a data request form and further instructions to access ACTwatch 
data (mlittrell@psi.org; or; info@actwatch.info). Please specify in the title of your 
email ‘ACTwatch data request’.
Ethical approval and consent to participate
The 2013 outlet survey protocols received ethical approval from the National 
Ethics Committee for Public Health Research at the University of Kinshasa 
(reference: ESP/CE/069/13). Provider interviews and product audits were 
completed only after administration of a standard informed consent form 
and provider consent to participate in the study. Providers had the option 
to end the interview at any point during the study. Standard measures were 
employed to maintain provider confidentiality and anonymity.
Funding
The ACTwatch project was funded by the Bill & Melinda Gates Foundation and 
the Department For International Development (DFID), Grant No (40068926). 
The funders played no role in the data collection, analysis or interpretation of 
the findings or the decision to submit the manuscript.
Received: 8 July 2016   Accepted: 15 December 2016
References
 1. WHO. World Malaria Report 2015. Geneva: World Health Organiza-
tion; 2015. http://www.who.int/malaria/publications/world-malaria-
report-2015/wmr2015-profiles.pdf?ua=1. Accessed 20 Apr 2015.
 2. CIA. DRC: The World Fact Book; 2016. https://www.cia.gov/library/
publications/the-world-factbook/geos/cg.html.
 3. Ferrari G, Ntuku HM, Schmidlin S, Diboulo E, Tshefu AK, Lengeler C. A 
malaria risk map of Kinshasa, Democratic Republic of Congo. Malar J. 
2016;15:27.
 4. Mulumba MP, Wery M, Ngimbi NN, Paluku K, Vander Stuyft P, De Muynck 
A. Childhood malaria in Kinshasa (Zaire). Influence of seasons, age, 
environment, and family social conditions (in French). Med Trop (Mars). 
1990;50:53–64.
 5. Kazadi W, Sexton JD, Bigonsa M, W’Okanga B, Way M. Malaria in primary 
school children and infants in Kinshasa, Democratic Republic of the 
Page 11 of 11ACTwatch Group et al. Malar J  (2017) 16:94 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Congo: surveys from the 1980s and 2000. Am J Trop Med Hyg. 2004;71(2 
Suppl):97–102.
 6. Shewchuk T, O’Connell KA, Goodman C, Hanson K, Chapman S, Chavasse 
D. The ACTwatch project: methods to describe anti-malarial markets in 
seven countries. Malar J. 2011;10:325.
 7. ACTwatch Group & ASF/Congo. Democratic Republic of the Congo Out-
let Survey Report 2009. Washington: DC. 2009. http://www.actwatch.info/
sites/default/files/content/outlet-reports/DRC%20OS%20Report_2009.
pdf. Accessed 4 Apr 2016.
 8. Littrell M, Gatakaa H, Evance I, Poyer S, Njogu J, Solomon T, et al. 
Monitoring fever treatment behaviour and equitable access to effective 
medicines in the context of initiatives to improve ACT access: baseline 
results and implications for programming in six African countries. Malar J. 
2011;10:327.
 9. O’Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, et al. 
Got ACTs? Availability, price, market share and provider knowledge of 
anti-malarial medicines in public and private sector outlets in six malaria-
endemic countries. Malar J. 2011;10:326.
 10. O’Connell KA, Poyer S, Solomon T, Munroe E, Patouillard E, Njogu J, et al. 
Methods for implementing a medicine outlet survey: lessons from the 
anti-malarial market. Malar J. 2013;12:52.
 11. ACTwatch Group & SFH/Nigeria. ACTwatch Study Reference Document: 
Nigeria Outlet Survey 2013; 2013.
 12. PSI/Tanzania. AGa. ACTwatch Study Reference Document: The United 
Republic of Tanzania Outlet Survey 2014. Washington, DC: PSI; 2016.
 13. PACE A. ACTwatch Study Reference Document: Uganda Outlet Survey 
2013; 2014.
 14. Team AIE. Independent evaluation of Phase 1 of the affordable medicines 
facility—malaria (AMFm), multi-country independent evaluation Report: 
Final Report. Calverton, Maryland and London: ICF International and 
London School of Hygiene and Tropical Medicine; 2012.
 15. CHAI. Case study: increasing availability of malaria rapid diagnostic tests 
in Tanzania’s private sector; 2015.
 16. Cohen J, Fink G, Berg K, Aber F, Jordan M, Maloney K, et al. Feasibility of 
distributing rapid diagnostic tests for malaria in the retail sector: evidence 
from an implementation study in Uganda. Plos ONE. 2012;7:e48296.
 17. DHS Macro Int. The Democratic of the Republic of Congo Demographic 
and Health Survey 2013-2014. Rockville, Maryland, U.S.A. 2014.
 18. WHO. World Malaria Report. Geneva: World Health Organization; 2015.
 19. WHO. Pre-qualification of medicines by WHO: Fact Sheet. Geneva: World 
Health Organization; 2013.
 20. ACTwatch Group & PSI/Kenya. ACTwatch study reference document 
Republic of Kenya 2014. Washington, DC: PSI;2016
 21. Nigeria AGSfFH. ACTwatch Study Reference Document Nigeria Outlet 
Survey 2013;2015.
 22. Newton P, Proux S, Green M, Smithuis F, Rozendaal J, Prakongpan S, et al. 
Fake artesunate in southeast Asia. Lancet. 2001;357:1948–50.
 23. WHO. WHO ‘Counterfeits: frequently asked questions’. Geneva: World 
Health Organization. http://www.who.int/medicines/services/counter-
feit/faqs/QandAsUpdateJuly11.pdf.
 24. Quality of artemisinin-containing antimalarials in Tanzania’s Private Sec-
tor—results from a Nationally Representative Outlet Survey. Am J Trop 
Med Hyg. 2015;92(6 Suppl):75–86.
 25. ACTwatch Group. ACTwatch Research Brief: Malaria Market Trends in 
Sub-Saharan Africa: 2009–2014. Washington, DC; 2015.
 26. Tougher S, Ye Y, Amuasi JH, Kourgueni IA, Thomson R, Goodman C, 
et al. Effect of the affordable medicines facility—malaria (AMFm) on the 
availability, price, and market share of quality-assured artemisinin-based 
combination therapies in seven countries: a before-and-after analysis of 
outlet survey data. Lancet. 2012;380:1916–26.
 27. WHO. Guidelines for the treatment of malaria. Geneva: World Health 
Organization; 2010.
 28. Poyer SP, Persoons F, Dale M, Onema W, Lara V, Charman N, et al. Trans-
forming the private sector market for quality malaria case management 
in Kinshasa, Democratic Republic of Congo. PSI; 2014.
